1. Home
  2. ALIM

as 05-17-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East operations are managed as three operating segments: U.S., International and Operating Cost It generates maximum revenue from U.S. Segment.

Founded: 2003 Country:
United States
United States
Employees: N/A City: ALPHARETTA
Market Cap: 167.6M IPO Year: 2010
Target Price: $8.00 AVG Volume (30 days): 67.9K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -1.23 EPS Growth: N/A
52 Week Low/High: $2.10 - $4.38 Next Earning Date: 05-14-2024
Revenue: $90,219,000 Revenue Growth: 61.75%
Revenue Growth (this year): 31.09% Revenue Growth (next year): 14.45%

Share on Social Networks: